-
PROVIDERS
REGISTER NOW
Navigating new frontiers in breast cancer care pathway intelligence: The role of providers and AI
Tuesday, July 29th
2:00pm PT, 4:00pm CT, 5:00pm ET -
LIFE SCIENCES
REGISTER NOW
Closing Care Gaps with AI: The Next Competitive Edge in Pharma
Monday, July 14
9am PT, 11am CT, 12pm ET -
PATIENTS
It's About Time
View the Tempus vision.
- RESOURCES
-
ABOUT US
View Job Postings
We’re looking for people who can change the world.
- INVESTORS
11/20/2024
University of Washington
Researchers at Tempus partnered with the University of Washington to study the genomic alteration (GA) landscape of pure urothelial (UC) and histologic subtypes of bladder cancer.
This analysis promises to yield insight into variant histology bladder cancers to better understand their lack of clinical response, and potentially identify modes of therapeutic intervention.
This study was presented at the ASCO GU Cancers Symposium in 2024.
-
07/01/2025Transforming R&D with Generative AI and Real-World Data
Mike Yasiejko, General Manager and Executive Vice President at Tempus, recently spoke with Andrew Mazar, PhD, Chief Operating Officer at Actuate Therapeutics, about the ways Tempus’ liquid biopsy (xF+) and methylation assays have been valuable to Actuate’s work and how the company has benefitted from the partnership
Watch now -
06/12/2025AI & ML in action: Demonstrating real-world impact in trial design & patient care
Discover how the Tempus platform leverages AI and ML to inform standard of care practices through health equity guidelines and drive insights that help refine clinical trial design. Engage with live demonstrations showcasing how our tools identify patients by modifying inclusion/exclusion criteria and leveraging patient queries. Explore how our tools integrate NCCN guidelines and empower life science teams to access current, actionable patient-journey insights. Learn how these real-world applications can drive progress in your clinical development initiatives.
Watch replay
Secure your recording now. -
06/09/2025Bridging the translational gap: The role of organoids in oncology R&D
This white paper explores the evolving role of organoids in oncology R&D, highlighting their potential as predictive preclinical models and their ability to reduce translational risk. Download for a comprehensive overview of the scientific landscape, key adoption barriers, emerging innovations, and how pharma companies leverage organoids to accelerate precision medicine.
Read more